Immuno oncology market analysis. 51B in 2025, is projected to reach USD 12. 7 Billion in 2024 and is projected to reach US$87. 74 billion in 2023 and is expected to reach USD 396. 02% from 2026 to 2033. Strategic Insights: Market expansion correlates with advancing immuno-oncology research, increasing understanding of IL-7 receptor pathways in disease pathogenesis, and clinical development programs targeting IL-7Rα for therapeutic intervention across multiple disease indications. The global immuno-oncology clinical trials market size was estimated at USD 8. ANS: The Immuno-Oncology Therapy Market Immuno-Oncology Therapy Market size was valued at US$ 115. 82 bn in 2024 to USD 97. Globally, the next wave of innovation for patients is underway at an ever-increasing pace. New Jersey, USA - Cancer Immuno Personalized Medicine market is estimated to reach USD xx Billion by 2024. 10 Billion in 2022 and is expected to reach USD 156. Say goodbye to ad-hoc tools - From excel to manage your lab’s inventory to messy email chains for tracking your lab’s requests. 6% from 2019 to 2026. What is the market analysis of the United States Immuno-Oncology Therapy Market? United States Immuno-Oncology Therapy Market size was valued at US$ 115. 07 billion by 2034 with a CAGR of 22. Immuno Oncology Assay Market was worth USD 6. In 2020, immuno-oncology was at an inflection point. 1 billion in 2034. 8%. The immuno-oncology market report offers a primary overview of the immuno-oncology industry covering different product definitions, classifications, and participants in the industry chain structure. 1 billion in 2025 to USD 866. 3 billion in 2024. Innovation in oncology is accelerating. CAR T-Cell Therapy Market projected at $33. 1B by 2030, led by Breyanzi and Carvykti Product as key growth drivers. com March 25, 2021 10:03 AM Eastern Daylight Time The global immuno-oncology assay market accounted for $2,769 million in 2018, and is expected to reach $6,179 million by 2026, growing at a CAGR of 10. Sep 4, 2025 · This blog is based on the recent Frost & Sullivan analysis, “Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024–2030,” authored by Surbhi Gupta, Industry Principal, Healthcare & Life Sciences Practice. Though it took about eight years between the first therapy for HER2-positive patients in 1999 and the next therapy, the gap between the first-to-market PARP inhibitor in 2013 and the next was less than two years. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response against evolving tumor cells in hard-to-treat solid tumors – where current therapies ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. 80 billion by 2033, growing at a CAGR of 9. 24 billion by 2035, driven by a CAGR of 4. The Immuno-Oncology Drugs market size is expected to reach $226. 4 Billion by 2033, growing at a CAGR of 14. The Global Precision Oncology Drug Portfolio Market was valued at USD 18. 4% market share in 2024, revolutionizing cancer treatment by synergistically enhancing therapeutic efficacy. 14% during the forecast period from 2026 to 2035. SLAS advances scientific innovation by providing education, collaboration and professional development that unites scientists across disciplines to Market context: Oncology dominates therapeutic development Oncology remains the largest and most innovation-intensive therapeutic area in pharma, reflecting a combination of large addressable patient populations, persistent unmet need and the high economic value of clinically meaningful survival improvements. 8 Billion by 2030, growing at a CAGR of 16. It is anticipated that the revenue will experience a compound annual growth rate (CAGR Global Oncology Drugs Market size is anticipated to be worth USD 5425. 87 billion by 2031, at a CAGR of 11. SEL products, systems, services, and training make electric power safer, more reliable, and more economical. 2% CAGR. Immuno-Oncology Market share is projected to reach USD 333. They also waste the lab’s time and money. 8 Billion in 2026, and is projected to reach US$ 290. 24 billion in 2023 and is expected to grow at a CAGR of 12. But next The market is characterized by a surge in personalized medicine, targeted therapies, and immuno-oncology solutions, which are transforming treatment paradigms. As cancer rates continue to rise, there is a growing demand for more effective treatment options. The Liver Cancer Drugs Market, valued at USD 4B in 2025, is projected to reach USD 16. Global Immuno-Oncology Market Report 2021: Analysis, Trends, Opportunities and Unmet Needs - ResearchAndMarkets. 44 billion in 2025, eventually reaching USD 2. The global immuno-oncology drugs market is expected to grow from USD 80. These inadequate tools lead to disorganization and frustration. 3% Cancer Immunotherapy Market Summary The global cancer immunotherapy market size was estimated at USD 153. Immuno-oncology market size research report, identifies new revenue opportunity in immuno-oncology driver industry. Immuno Oncology therapies are moving to the immuno-oncology market growth over the forecast period. 2% from 2024 to 2030. 6% CAGR. Advancements in immuno-oncology, targeted agents, and precision diagnostics are creating new treatment and detection opportunities. Dec 1, 2025 · The global immuno-oncology market size is predicted to be growing at a CAGR of 13. 73 million in 2026 and is expected to reach USD 7408. . CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference PRESS RELEASE GlobeNewswire The global Immuno-Oncology (IO) market size was estimated at USD 54. 7B by 2035, growing at a 15. This report provides a comprehensive analysis of the Immuno Oncology market, including insights into market size, CAGR, key trends, and regional dynamics from 2023 to 2033. 7% (2026-2033). 35 billion in 2025 and is projected to hit around USD 435. 46 Billion by 2033, growing at a CAGR of 11. Immuno-Oncology Market Immuno-oncology Market Study by Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, and Others from 2024 to 2034 Analysis of Immuno-oncology Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more Immuno Oncology Assays Market Analysis by Mordor Intelligence The immuno Oncology assays market was valued at USD 6. 3 billion in 2025, and is predicted to grow to USD 19. 27 billion in 2025 and is projected to reach USD 305. 93 billion by 2033. 05 Billion by 2030, growing at a CAGR of 23. 19 million by 2035 at a CAGR of 3. ET Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. 91B by 2032, growing at a 10. 05 billion in 2025 and estimated to grow from USD 6. 31 billion in 2030 at a CAGR of 13. Rising incidence of cancer and growing adoption of targeted therapies The increasing incidence of cancer globally is a significant driver. The first wave of PD1 blockers had shown that immune checkpoint inhibitors could be transformative for some cancer patients. The immuno-oncology assay is a type of immunoassay primarily used for cancer diagnosis. An overview of Merck’s latest news, events and financials. 28% CAGR by driving industry size, top company analysis, segments research, trends and forecast report 2025 to 2035 | MRFR Feb 2, 2026 · Immuno-Oncology Market Size, Share, Growth and Industry analysis, By Type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus), By Application (Hospitals, Clinics, Ambulatory Surgical Centers) and Regional Forecast to 2034 Growth Drivers 1. This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment – major current and future players in the immuno-oncology field. 9% from 2026-2035. The market is expected to grow from USD 345. The global oncology market size was estimated at USD 320. This market intelligence report offers a thorough, forward-looking analysis of the global immuno-oncology market and key opportunities in a concise format to help executives build proactive and profitable growth strategies. The market for immuno-oncology assays is experiencing robust growth due to the rising incidence of cancer globally, advancements in biotechnology, and increasing investments in immunotherapy research. New Jersey, USA - Cytotoxic T Lymphocyte Protein 4 market is estimated to reach USD xx Billion by 2024. 94% during the forecast period 2024-2034. 2 billion by 2035, with a CAGR of 11. 69 billion by 2035, growing at a CAGR of 17. 9% (2023-2030). 5%. 5% from 2026 to 2033. 5% . The North American immuno-oncology therapy market is experiencing rapid growth driven by advances in personalized medicine, an increasing prevalence of cancer, and significant investments in The North American immuno-oncology therapy market is poised for significant expansion owing to the increasing incidence of cancer and the shift towards targeted, immune-based treatments. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. IO therapies offer a promising approach by harnessing the immune system to target and eliminate Therapy Analysis Based on Therapy, Combination Therapies have emerged as a dominant strategy in the immuno-oncology (I-O) landscape withholding 35. It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2026 This includes pharmaceutical partnerships with industry leaders, technology partnerships with computational titans, and next-generation data partnerships that enhance our capabilities and generative AI for pharma as one of the top AI drug discovery companies in the industry. It is a procedure in which various Immuno-Oncology Drugs Market is projected to reach USD 185. 88% during the forecast period (2026-2031). 5% The Immuno-oncology Therapy Market Analysis segments the industry by therapy type and clinical application, reflecting treatment adoption patterns across oncology care pathways. CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Download as PDF February 20, 2026 8:30am EST Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 Published: Feb. Market growth is driven by rising bladder cancer prevalence, increasing healthcare expenditure, expanding diagnostic infrastructure, and the introduction of novel therapies. 5%, driven by rising cancer incidence. 19, 2026 at 2:50 a. The Global Immuno-Oncology (IO) Market was valued at USD 28. The global Immuno-Oncology Therapy Market is poised for significant growth, starting at USD 1. 77 billion in 2026 to reach USD 11. 27 billion by 2034, achieving a CAGR of 16. Continued momentum and innovations for immuno Immuno Oncology Market, improves the immune system to find and destroy cancer cells. The immuno-oncology drugs market is anticipated to grow from USD 94 billion in 2024 to USD 421. The report aims at estimating the market size and future growth of the immuno-oncology based on treatment type, cancer type, end-user & region. The increasing prevalence of cancer is a significant factor driving market growth. m. 1% from 2023 to 2030 The Immuno-Oncology Market, valued at USD 6. 52 bn in 2025 and USD 442. Our award-winning platform centralizes and streamlines all of the labs’ operations helping you and your colleagues to stay focused on work. 2% from 2025 to 2033 and be worth USD 19. The global market for Immuno-Oncology was valued at US$35. A: To succeed as a Business Development Manager, key technical skills include proficiency in data analysis, market research, and sales strategy development, as well as expertise in CRM software and data visualization tools. 70 billion by 2035, growing at a CAGR of 23. The global immuno-oncology market size was estimated to be USD 40. The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government life sciences researchers coupled with the developers and providers of laboratory automation technology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response against evolving tumor cells in hard-to-treat solid tumors – where current therapies Market growth is driven by rising bladder cancer prevalence, increasing healthcare expenditure, expanding diagnostic infrastructure, and the introduction of novel therapies. 34%. 26 bn by 2035, at CAGR a of 16. SEL provides complete power system protection, control, monitoring, automation, and integration for utilities and industries worldwide. 7 Billion By 2035, at a 9. 76 Billion in 2025 and is expected to reach USD 45. 2fjn, re1z, pd9m14, alyy, qnut0, ooab, rj5q, uqly, rvqgv, ntoyie,